WithdrawnNCT01908452

Pyridoxal Kinase Activity in Tardive Dyskinesia

Medication studyAges 18–65IsraelSchizophrenia

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Beersheba and 2 more locationsSee all locations and recruitment
Study phase: Phase 3

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateJuly 2011

Recruitment status: Withdrawn
Enrollment listed in the registry: 0
Sponsor: Beersheva Mental Health Center
Sponsor type: Hospital / academic medical center
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Israel
Age range: From 18 Years to 65 Years
Official registry ID: NCT01908452
Official title: Show the full official title
Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6

Withdrawn

Beersheba · Hadera · Haifa

FAQ

Who is behind this study?

The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Pyridoxine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as withdrawn.